Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma

Table 2

Distribution of ATAD2 and clinicopathological characteristics from institutional HCC patients.

Characteristics	No. of patients	ATAD2
		Low expression	High expression
Tissue
Tumor	80	28	52	8.046	0.006
Normal tumor	20	14	6
Gender
Male	66	25	41	1.374	0.357
Female	14	3	11
Age (year)
<50	25	7	18	0.783	0.454
≥50	55	21	34
Tumor size
≥5 cm	35	7	28	6.154	0.018
<5 cm	45	21	24
Metastasis
Yes	30	5	25	7.092	0.009
No	50	23	27
Invasion
Yes	27	6	21	2.925	0.136
No	53	22	31
Cirrhosis
Yes	76	27	49	0.185	1.000
No	4	1	3
HBsAg
Positive	64	22	42	0.055	1.000
Negative	16	6	10
AFP
<200 ng/dl	57	25	32	6.841	0.010
≥200 ng/dl	23	3	20
TNM stage
I + II	50	22	28	4.747	0.033
III + IV	30	6	24
Differentiation
WD	35	16	19	3.391	0.184
MD	35	10	25
PD	10	2	8

Abbreviations: WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated.